PMAM
RIGL icon

Picton Mahoney Asset Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Picton Mahoney Asset Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-163
Closed -$3K – 1142
2025
Q1 		$3K Sell
163
-1,134
-87% -$23K ﹤0.01% 674
2024
Q4 		$22K Buy
1,297
+26
+2% +$499 ﹤0.01% 526
2024
Q3 		$21K Buy
1,271
+818
+181% +$9.62K ﹤0.01% 462
2024
Q2 		$3K Buy
+453
New +$4.74K ﹤0.01% 552

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CLGM
Capitolis Liquid Global Markets New York $15.7B AUM 30.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Picton Mahoney Asset Management's RIGL Position: Q2 2025 in Review

Picton Mahoney Asset Management sold out of Rigel Pharmaceuticals (RIGL) in Q2 2025, closing a stake of 163 shares — an estimated $3K sold.

Picton Mahoney Asset Management first reported a position in RIGL in Q2 2024 and held it in 4 quarters. The position peaked at $22K in Q4 2024. 125 funds tracked by Wall St. Rank hold RIGL as of Q2 2025.

  • Picton Mahoney Asset Management reported no remaining Rigel Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Picton Mahoney Asset Management sold 163 Rigel Pharmaceuticals shares in Q2 2025, an estimated $3K.
  • Picton Mahoney Asset Management first reported a position in Rigel Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Picton Mahoney Asset Management's Rigel Pharmaceuticals position peaked at $22K in Q4 2024.
  • 125 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2025.

Based on Picton Mahoney Asset Management's 13F filing for Q2 2025, filed 12 Aug 2025.